Total Payments
$839,228
2024 Payments
$47,643
Companies
53
Transactions
1,354
Medicare Patients
3,179
Medicare Billing
$374,588
Payment Breakdown by Category
Other$714,921 (85.2%)
Consulting$59,458 (7.1%)
Travel$37,750 (4.5%)
Food & Beverage$26,630 (3.2%)
Education$290.62 (0.0%)
Gifts$178.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $714,921 | 389 | 85.2% |
| Consulting Fee | $59,458 | 19 | 7.1% |
| Travel and Lodging | $37,750 | 172 | 4.5% |
| Food and Beverage | $26,630 | 736 | 3.2% |
| Education | $290.62 | 35 | 0.0% |
| Gift | $178.20 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $288,085 | 359 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $211,054 | 285 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $197,261 | 204 | $0 (2024) |
| Novo Nordisk Inc | $59,604 | 104 | $0 (2024) |
| Amgen Inc. | $31,236 | 70 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $26,876 | 42 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $12,418 | 27 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,927 | 4 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $3,073 | 21 | $0 (2021) |
| MannKind Corporation | $824.47 | 36 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,643 | 113 | Lilly USA, LLC ($23,401) |
| 2023 | $58,770 | 135 | Lilly USA, LLC ($28,784) |
| 2022 | $42,301 | 109 | Novo Nordisk Inc ($17,630) |
| 2021 | $39,841 | 124 | Novo Nordisk Inc ($15,439) |
| 2020 | $47,945 | 106 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,358) |
| 2019 | $128,120 | 203 | AstraZeneca Pharmaceuticals LP ($49,955) |
| 2018 | $195,911 | 245 | Lilly USA, LLC ($85,864) |
| 2017 | $278,698 | 319 | AstraZeneca Pharmaceuticals LP ($93,726) |
All Payment Transactions
1,354 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $5.86 | General |
| Category: Automated insulin delivery system | ||||||
| 12/19/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $22.46 | General |
| 11/22/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Endocrinology | ||||||
| 11/15/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $37.69 | General |
| Category: Endocrinology | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Bone Health | ||||||
| 11/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Obesity | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: DIABETES | ||||||
| 10/29/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/23/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: IMMUNOLOGY | ||||||
| 10/19/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Endocrinology | ||||||
| 10/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: Obesity | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: DIABETES | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: DIABETES | ||||||
| 10/01/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $135.84 | General |
| Category: Insulin Pump | ||||||
| 09/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/11/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $100.99 | General |
| Category: Automated insulin delivery system | ||||||
| 09/11/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Automated insulin delivery system | ||||||
| 09/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: Diabetes | ||||||
| 09/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: Cardio-renal | ||||||
| 09/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.75 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 08/21/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Cardiology | ||||||
| 08/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $0.96 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 783 | 1,490 | $241,515 | $96,697 |
| 2022 | 7 | 797 | 1,519 | $245,380 | $95,099 |
| 2021 | 6 | 742 | 1,396 | $224,700 | $93,410 |
| 2020 | 8 | 857 | 1,341 | $245,580 | $89,381 |
Total Patients
3,179
Total Services
5,746
Medicare Billing
$374,588
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 359 | 779 | $175,275 | $71,453 | 40.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $23,375 | $11,030 | 47.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 32 | $9,600 | $4,520 | 47.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 224 | 451 | $18,040 | $4,173 | 23.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 63 | 123 | $9,225 | $3,267 | 35.4% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 20 | 20 | $6,000 | $2,256 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 354 | 784 | $176,400 | $70,366 | 39.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 79 | 79 | $21,725 | $9,689 | 44.6% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 235 | 487 | $19,480 | $4,538 | 23.3% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 34 | 35 | $10,500 | $4,071 | 38.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 66 | 105 | $7,875 | $2,794 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $4,500 | $1,865 | 41.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $4,900 | $1,775 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 334 | 702 | $157,950 | $66,705 | 42.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 87 | 87 | $23,925 | $11,780 | 49.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 48 | $14,400 | $6,301 | 43.8% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 231 | 480 | $19,200 | $4,622 | 24.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $4,200 | $2,143 | 51.0% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 31 | 67 | $5,025 | $1,860 | 37.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 380 | 746 | $167,850 | $58,741 | 35.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 83 | 83 | $29,050 | $13,367 | 46.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 33 | 34 | $10,200 | $4,109 | 40.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 29 | 29 | $7,975 | $3,299 | 41.4% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 234 | 337 | $13,480 | $3,230 | 24.0% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2020 | 22 | 23 | $6,900 | $2,900 | 42.0% |
About Dr. Manisha Chandalia, MD
Dr. Manisha Chandalia, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Baytown, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750347217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manisha Chandalia, MD has received a total of $839,228 in payments from pharmaceutical and medical device companies, with $47,643 received in 2024. These payments were reported across 1,354 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($714,921).
As a Medicare-enrolled provider, Chandalia has provided services to 3,179 Medicare beneficiaries, totaling 5,746 services with total Medicare billing of $374,588. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Baytown, TX
- Active Since 04/25/2006
- Last Updated 10/04/2022
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1750347217
Products in Payments
- JARDIANCE (Drug) $305,449
- TRULICITY (Drug) $159,415
- FARXIGA (Drug) $158,046
- BYDUREON (Drug) $52,189
- Repatha (Biological) $30,413
- INVOKANA (Drug) $26,823
- Rybelsus (Drug) $18,403
- RYBELSUS (Drug) $14,750
- Saxenda (Drug) $12,008
- PRALUENT (Drug) $11,991
- Ozempic (Drug) $11,929
- EYLEA (Biological) $3,790
- STEGLATRO (Drug) $2,687
- MOUNJARO (Drug) $2,274
- AFREZZA (Drug) $824.47
- EVENITY (Biological) $711.56
- Kerendia (Drug) $468.45
- Vascepa (Drug) $461.37
- Omnipod (Device) $412.65
- JANUVIA (Drug) $287.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.